Nanobac Pharmaceuticals (NNBP)

[weebie]

NNBP latest 10k was Dec 2007. Check out the website...under construction....nothing....

www.nanobaclabs.com
1 Employees
Founded in 1994

Company Description
Contact Info

4730 North Habana Avenue

Suite 205

Tampa, FL 33614

United States

Phone: [phone]

Fax: [phone]
www.nanobaclabs.com

Nanobac Pharmaceuticals, Incorporated, a bio-lifescience company, engages in the discovery and development of products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs). IVD products (blood and tissue tests) include assays, proprietary antibodies and reagents for recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials. Research The company’s scientist has formed multidisciplinary alliances with top researchers, including: Marshall Stoller, University of California San Francisco; Rune Eliasson, Sweden; Hojatollah Vali, McGill University, Canada; Mayo Clinic, Rochester, Minnesota; University of South Florida; Iowa State University; D. Shoskes, Cleveland Clinic; Garcia-Cuerpo, Spain; China Ghangsha group; Sommer, Univ. of Ulm; Pretorius, South-Africa; G. Epstein/J.T. Salonen; Tom & Marcia Hjelle, Univ. of Illinois; Y. Av-Gay, University of British Columbia; and R. Berger, and Miami Heart Institute, Miami Florida. The company generally retains the rights for the commercialization of intellectual property that result from these collaborative studies. In 2004, the company entered into a Space Act Agreement with NASA’s Johnson Space Center (JSC), Houston Texas, to collaborate on the research of nanobacterium sanguineum and its nature and role in pathological calcification, including the detection and treatment of the pathogen. The company owns the rights for the commercialization of intellectual property that results from its collaborative research at NASA JSC. However, the U.S. Federal Government retains the right to use this intellectual property for U.S. Government purposes without compensation to the company. Urological Diseases The company has been working with scientists at NASA to research the effects of CNPs in the formation of kidney stones during space flights. Cardiovascular Diseases The company is continuing its research of the relationship between CNPs and heart disease and has expanded its research to include other diseases involving pathological calcification. Other Opportunities The company develops and applies methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials or production substrates. The company’s contamination control program focuses on host cell lines, animal and human derived materials, raw materials, availability of diagnostic procedures, and downstream processes capable of inactivating or removing contaminants. Markets The company initially focuses its drug discovery business in the United States. The company would also develop markets in the European Union through the operations of its Finnish Subsidiary, Nanobac OY. Competitors The company’s competitors for academic researchers and clinical laboratories with in vitro diagnostic test kits includes diagnostic companies, such as, Roche, Abbott, Bayer, Johnson & Johnson, and Dade Behring. History Nanobac Pharmaceuticals, Incorporated was incorporated in 1994.